| Literature DB >> 30947876 |
Sasan Sakiani1, David E Kleiner2, Theo Heller3, Christopher Koh4.
Abstract
Cystic fibrosis liver disease (CFLD) remains the third leading cause of death in patients with cystic fibrosis. Although most patients with CFLD present in childhood, recent studies suggest a second wave of liver disease in adulthood. There are no clear guidelines for diagnosing CFLD. Treatment options for CFLD remain limited, and while UDCA is widely used, its long-term benefit is unclear. Those who develop hepatic decompensation or uncontrolled variceal bleeding may benefit from liver transplant, either alone, or in combination with lung transplant. Published by Elsevier Inc.Entities:
Keywords: CFLD; Cystic fibrosis liver disease; Focal biliary cirrhosis; Liver disease in cystic fibrosis; Non-cirrhotic portal hypertension
Mesh:
Substances:
Year: 2019 PMID: 30947876 PMCID: PMC6452885 DOI: 10.1016/j.cld.2018.12.008
Source DB: PubMed Journal: Clin Liver Dis ISSN: 1089-3261 Impact factor: 6.126